M701 is a bispecific antibody targeting CD3 on T-cells and EpCAM on tumor cells to stimulate T-cell-mediated tumor cell death. It is being developed for the treatment of malignant ascites by redirecting T-cells to EpCAM-expressing tumors. M.W 125.84 kDa